ZHX2 and cancer

Abstract

FU Shi-Jie, GUO Qing-He. ZHX2 and cancer[J]. Journal of International Oncology, 2013, 40(12): 905-907.

［1］ Kawata H, Yamada K, Shou Z, et al. Zincfingers and homeoboxes (ZHX) 2, a novel member of the ZHX family as a transcriptional repressor. Biochem J, 2003, 373 (Pt 3): 747757. ［2］ Shen H, Luan F, Liu H, et al. ZHX2 is a repressor of alphafetoprotein expression in human hepatoma cell lines. J Cell Mol Med, 2008, 12(68): 27722780. ［3］ Li MS, Li PF, He SP, et al. The promoting molecular mechanism of alphafetoprotein on the growth of human hepatoma Bel7402 cell line. World J Gastroenterol, 2002, 8(3): 469475. ［4］ Cavin LG, Venkatraman M, Factor VM, et al. Regulation of alphafetoprotein by nuclear factorkappaB protects hepatocytes from tumor necrosis factoralpha cytotoxicity during fetal liver development and hepatic oncogenesis. Cancer Res, 2004, 64 (19): 70307038. ［5］ Perincheri S, Dingle RW, Peterson ML, et al. Hereditary persistence of alphafetoprotein and H19 expression in liver of BALB/cJ mice is due to a retrovirus insertion in the Zhx2 gene. Proc Natl Acad Sci USA, 2005, 102(2): 396401. ［6］ Lv Z, Zhang M, Bi J, et al. Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma. Am J Clin Pathol, 2006, 125(5): 740746. ［7］ Kittaka N, Takemasa I, Takeda Y, et al. Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic data. Eur J Cancer, 2008, 44(6): 885897. ［8］ Shirakawa H, Suzuki H, Shimomura M, et al. Glypican3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci, 2009, 100(8): 14031407. ［9］ Morford LA, Davis C, Jin L, et al. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alphafetoprotein regulator 2. Hepatology, 2007, 46(5): 15411547. ［10］ Maurel M, Dejeans N, Taouji S, et al. MicroRNA1291mediated silencing of IRE1α enhances Glypican3 expression. RNA, 2013, 19(6): 778788. ［11］ Shih HC, Shiozawa T, Kato K, et al. Immunohistochemical expression of cyclins, cyclindependent kinases, tumorsuppressor gene products, Ki67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol, 2003, 34(5): 471478. ［12］ MüllerTidow C, Metzger R, Kügler K, et al. Cyclin E is the only cyclindependent kinase 2associated cyclin that predicts metastasis and survival in early stage nonsmall cell lung cancer. Cancer Res, 2001, 61(2): 647653. ［13］ Ohashi R, Gao C, Miyazaki M, et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res, 2001, 21(1B): 657662. ［14］ Yue X, Zhang Z, Liang X, et al. Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclin A and E. Gastroenterology, 2012, 142(7): 15591570. ［15］ Gargalovic PS, Erbilgin A, Kohannim O, et al. Quantitative trait locus mapping and identification of Zhx2 as a novel regulator of plasma lipid metabolism. Circ Cardiovasc Genet, 2010, 3(1): 6067. ［16］ Watts GS, Oshiro MM, Junk DJ, et al. The acetyltransferase p300/CBPassociated factor is a p53 target gene in breast tumor cells. Neoplasia, 2004, 6(3): 187194. ［17］ Cui R, Nguyen TT, Taube JH, et al. Family members p53 and p73 act together in chromatin modification and direct repression of alphafetoprotein transcription. J Biol Chem, 2005, 280(47): 3915239160. ［18］ Lu ZL, Luo DZ, Wen JM. Expression and significance of tumorrelated genes in HCC. World J Gastroenterol, 2005, 11(25): 38503854. ［19］ Aoki T, Miyamoto A, Marubashi S, et al. Clinical value of alterations in p73 gene, related to p53 at 1p36, in human hepatocellular carcinoma. Int J Oncol, 2004, 24(2): 441446. ［20］ Legartova S, HarnicarovaHorakova A, Bartova E, et al. Expression of RAN, ZHX2, and CHC1L genes in multiple myeloma patients and in myeloma cell lines treated with HDAC and Dnmts inhibitors. Neoplasma, 2010, 57(5): 482487. ［21］ Armellini A, Sarasquete ME, GarcíaSanz R, et al. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. Br J Haematol, 2008, 141(2): 212215. ［22］魏晶晶, 吕自力, 党裔武, 等. 结直肠癌中ZHX2蛋白表达的检测及其临床病理意义. 临床与实验病理学杂志, 2012, 28(2): 128131. ［23］ Hoffman WH, Biade S, Zilfou JT, et al. Transcriptional repression of the antiapoptotic surviving gene by wild type p53. J Biol Chem, 2002, 277(5): 32473257. ［24］ Morachis JM, Murawsky CM, Emerson BM. Regulation of the p53 transcription response by structurally diverse core promoters. Genes Dev, 2010, 24(2): 135147. ［25］陈其军, 吕自力, 党裔武, 等. 转录抑制因子ZHX2在胃癌组织中的表达及临床意义. 世界华人消化杂志, 2011, 19 (30): 31633167.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments